Cargando…

Assessment of Glycosylated Hemoglobin Outcomes Following an Enhanced Medication Therapy Management Service via Telehealth

(1) Background: Regular contact with a medication therapy management (MTM) pharmacist is shown to improve patients’ understanding of their condition; however, continued demonstration of the value of a pharmacist delivered comprehensive medication review (CMR) using enhanced MTM services via teleheal...

Descripción completa

Detalles Bibliográficos
Autores principales: Bingham, Jennifer M., Stanislaw, Jennifer, Warholak, Terri, Scovis, Nicole, Axon, David R., Turgeon, Jacques, Marupuru, Srujitha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8296452/
https://www.ncbi.nlm.nih.gov/pubmed/34207164
http://dx.doi.org/10.3390/ijerph18126560
_version_ 1783725642046504960
author Bingham, Jennifer M.
Stanislaw, Jennifer
Warholak, Terri
Scovis, Nicole
Axon, David R.
Turgeon, Jacques
Marupuru, Srujitha
author_facet Bingham, Jennifer M.
Stanislaw, Jennifer
Warholak, Terri
Scovis, Nicole
Axon, David R.
Turgeon, Jacques
Marupuru, Srujitha
author_sort Bingham, Jennifer M.
collection PubMed
description (1) Background: Regular contact with a medication therapy management (MTM) pharmacist is shown to improve patients’ understanding of their condition; however, continued demonstration of the value of a pharmacist delivered comprehensive medication review (CMR) using enhanced MTM services via telehealth is needed. The study aimed to describe a pilot program designed to improve type 2 diabetes mellitus (T2DM) management through enhanced condition specific MTM services. (2) Methods: This retrospective study included patients with T2DM aged 40–75 years who received a pharmacist-delivered CMR between January and December 2018. An evaluation of glycosylated hemoglobin (HbA1c) values 3 months pre- and post-CMR was performed. Wilcoxon signed-rank and chi-square tests were used. (3) Results: Of 444 eligible patients, a majority were female (58%) with a median age of 70 years. Median HbA1c values post-CMR were lower than pre-CMR (median 7.1% range 4.5–13.6; median 7.4% range 4.5–13.9, respectively; p = 0.009). There were fewer participants with HbA1c >9% post-CMR (n = 66) than pre-CMR (n = 80; p < 0.001) and more with HbA1C <6.5% post-CMR (n = 151) than pre-CMR (n = 130; p < 0.001). (4) Conclusion: This program evaluation highlighted the value of an enhanced condition specific MTM service via telehealth. Patients had improved HbA1c values three months after receiving a single pharmacist delivered CMR.
format Online
Article
Text
id pubmed-8296452
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82964522021-07-23 Assessment of Glycosylated Hemoglobin Outcomes Following an Enhanced Medication Therapy Management Service via Telehealth Bingham, Jennifer M. Stanislaw, Jennifer Warholak, Terri Scovis, Nicole Axon, David R. Turgeon, Jacques Marupuru, Srujitha Int J Environ Res Public Health Article (1) Background: Regular contact with a medication therapy management (MTM) pharmacist is shown to improve patients’ understanding of their condition; however, continued demonstration of the value of a pharmacist delivered comprehensive medication review (CMR) using enhanced MTM services via telehealth is needed. The study aimed to describe a pilot program designed to improve type 2 diabetes mellitus (T2DM) management through enhanced condition specific MTM services. (2) Methods: This retrospective study included patients with T2DM aged 40–75 years who received a pharmacist-delivered CMR between January and December 2018. An evaluation of glycosylated hemoglobin (HbA1c) values 3 months pre- and post-CMR was performed. Wilcoxon signed-rank and chi-square tests were used. (3) Results: Of 444 eligible patients, a majority were female (58%) with a median age of 70 years. Median HbA1c values post-CMR were lower than pre-CMR (median 7.1% range 4.5–13.6; median 7.4% range 4.5–13.9, respectively; p = 0.009). There were fewer participants with HbA1c >9% post-CMR (n = 66) than pre-CMR (n = 80; p < 0.001) and more with HbA1C <6.5% post-CMR (n = 151) than pre-CMR (n = 130; p < 0.001). (4) Conclusion: This program evaluation highlighted the value of an enhanced condition specific MTM service via telehealth. Patients had improved HbA1c values three months after receiving a single pharmacist delivered CMR. MDPI 2021-06-18 /pmc/articles/PMC8296452/ /pubmed/34207164 http://dx.doi.org/10.3390/ijerph18126560 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bingham, Jennifer M.
Stanislaw, Jennifer
Warholak, Terri
Scovis, Nicole
Axon, David R.
Turgeon, Jacques
Marupuru, Srujitha
Assessment of Glycosylated Hemoglobin Outcomes Following an Enhanced Medication Therapy Management Service via Telehealth
title Assessment of Glycosylated Hemoglobin Outcomes Following an Enhanced Medication Therapy Management Service via Telehealth
title_full Assessment of Glycosylated Hemoglobin Outcomes Following an Enhanced Medication Therapy Management Service via Telehealth
title_fullStr Assessment of Glycosylated Hemoglobin Outcomes Following an Enhanced Medication Therapy Management Service via Telehealth
title_full_unstemmed Assessment of Glycosylated Hemoglobin Outcomes Following an Enhanced Medication Therapy Management Service via Telehealth
title_short Assessment of Glycosylated Hemoglobin Outcomes Following an Enhanced Medication Therapy Management Service via Telehealth
title_sort assessment of glycosylated hemoglobin outcomes following an enhanced medication therapy management service via telehealth
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8296452/
https://www.ncbi.nlm.nih.gov/pubmed/34207164
http://dx.doi.org/10.3390/ijerph18126560
work_keys_str_mv AT binghamjenniferm assessmentofglycosylatedhemoglobinoutcomesfollowinganenhancedmedicationtherapymanagementserviceviatelehealth
AT stanislawjennifer assessmentofglycosylatedhemoglobinoutcomesfollowinganenhancedmedicationtherapymanagementserviceviatelehealth
AT warholakterri assessmentofglycosylatedhemoglobinoutcomesfollowinganenhancedmedicationtherapymanagementserviceviatelehealth
AT scovisnicole assessmentofglycosylatedhemoglobinoutcomesfollowinganenhancedmedicationtherapymanagementserviceviatelehealth
AT axondavidr assessmentofglycosylatedhemoglobinoutcomesfollowinganenhancedmedicationtherapymanagementserviceviatelehealth
AT turgeonjacques assessmentofglycosylatedhemoglobinoutcomesfollowinganenhancedmedicationtherapymanagementserviceviatelehealth
AT marupurusrujitha assessmentofglycosylatedhemoglobinoutcomesfollowinganenhancedmedicationtherapymanagementserviceviatelehealth